Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
Top Cited Papers
Open Access
- 8 August 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 122 (6), 981-987
- https://doi.org/10.1182/blood-2013-03-491514
Abstract
Key Points This study is a retrospective analysis of long-term outcomes of patients with FL treated at Stanford University for 4 decades. Study results showed significant improvement in OS in patients with FL despite no change in event-free survival after first-line therapy.Keywords
This publication has 34 references indexed in Scilit:
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLBlood, 2012
- Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 StudyJournal of Clinical Oncology, 2009
- Follicular Lymphoma in the United States: First Report of the National LymphoCare StudyJournal of Clinical Oncology, 2009
- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyBlood, 2008
- Introduction of rituximab in front‐line and salvage therapies has improved outcome of advanced‐stage follicular lymphoma patientsCancer, 2007
- New Treatment Options Have Changed the Survival of Patients With Follicular LymphomaJournal of Clinical Oncology, 2005
- Improved Survival of Follicular Lymphoma Patients in the United StatesJournal of Clinical Oncology, 2005
- The Natural History of Initially Untreated Low-Grade Non-Hodgkin's LymphomasThe New England Journal of Medicine, 1984
- 352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence DataBiometrics, 1973
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958